

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/261220108>

Semisynthesis, ex vivo evaluation, and SAR studies of coumarin derivatives as potential antiasthmatic drugs

ARTICLE *in* EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY · MARCH 2014

Impact Factor: 3.45 · DOI: 10.1016/j.ejmech.2014.03.029 · Source: PubMed

CITATIONS

7

READS

61

6 AUTHORS, INCLUDING:



Gabriel Navarrete-Vázquez

Universidad Autónoma del Estado de Morelos

71 PUBLICATIONS 1,103 CITATIONS

SEE PROFILE



Sergio Nemorio Hidalgo Figueroa

Metropolitan Autonomous University

14 PUBLICATIONS 53 CITATIONS

SEE PROFILE



Yolanda Rios Gomez

Universidad Autónoma del Estado de Morelos

86 PUBLICATIONS 662 CITATIONS

SEE PROFILE




Samuel Estrada-Soto

Universidad Autónoma del Estado de Morelos

88 PUBLICATIONS 821 CITATIONS

SEE PROFILE

AUTHOR QUERY FORM

 ELSEVIER	Journal: EJMECH Article Number: 6812	Please e-mail or fax your responses and any corrections to: E-mail: corrections.esco@elsevier.tnq.co.in Fax: +31 2048 52789
--	---	---

Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. Note: if you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of your paper please return your corrections within 48 hours.

For correction or revision of any artwork, please consult <http://www.elsevier.com/artworkinstructions>.

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof.

Location in article	Query / Remark: Click on the Q link to find the query's location in text Please insert your reply or correction at the corresponding line in the proof
Q1 Q2	<p>Please provide a definition for the significance of bold given in the Table 2.</p> <p>Please confirm that given names and surnames have been identified correctly.</p> <div data-bbox="304 1151 895 1332" style="border: 1px solid black; padding: 10px;"> <p>Please check this box or indicate your approval if you have no corrections to make to the PDF file</p> <div data-bbox="791 1210 879 1295" style="border: 1px solid black; width: 55px; height: 40px; display: inline-block; margin-left: 10px;"></div> </div>

Thank you for your assistance.



Contents lists available at ScienceDirect

European Journal of Medicinal Chemistry


journal homepage: <http://www.elsevier.com/locate/ejmech>

Graphical Abstract

Semisynthesis, *ex vivo* evaluation, and SAR studies of coumarin derivatives as potential antiasthmatic drugs

pp. 1–9

Amanda Sánchez-Recillas, Gabriel Navarrete-Vázquez*, Sergio Hidalgo-Figueroa, María Yolanda Ríos, Maximiliano Ibarra-Barajas, Samuel Estrada-Soto*



* Corresponding authors.

Highlights

- Eighteen coumarin derivatives were semisynthesized with potential antiasthmatic properties.
- Results indicate that ether derivatives **1–3**, **7–9** and **13–15** showed the best relaxant activity.
- Compound **2** (42 μM) was the most potent of the entire series, being 4-times more active than theophylline (positive control).



Contents lists available at ScienceDirect

European Journal of Medicinal Chemistry

journal homepage: <http://www.elsevier.com/locate/ejmech>

Original article

Semisynthesis, *ex vivo* evaluation, and SAR studies of coumarin derivatives as potential antiasthmatic drugsAmanda Sánchez-Recillas^{a,1}, Gabriel Navarrete-Vázquez^{b,*,2}, Sergio Hidalgo-Figueroa^b,
María Yolanda Ríos^c, Maximiliano Ibarra-Barajas^d, Samuel Estrada-Soto^{a,*,2}^a Laboratorio de Farmacognosia y Química de Productos Naturales, Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Avenida Universidad 1001, Col. Chamilpa, 62209 Cuernavaca, Morelos, Mexico^b Laboratorio de Química Farmacéutica, Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Avenida Universidad 1001, Col. Chamilpa, 62209 Cuernavaca, Morelos, Mexico^c Centro de Investigaciones Químicas, Universidad Autónoma del Estado de Morelos, Avenida Universidad 1001, Col. Chamilpa, 62209 Cuernavaca, Morelos, Mexico^d Unidad de Biomedicina, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, 54090 Tlalnepantla, Estado de México, Mexico

ARTICLE INFO

Article history:

Received 5 November 2013

Received in revised form

8 March 2014

Accepted 11 March 2014

Available online xxx

Keywords:

Asthma

Coumarins

Natural products

Pharmacophoric group

SAR

Tracheal rings

ABSTRACT

Asthma is a chronic inflammatory disorder that causes contraction in the smooth muscle of the airway and blocking of airflow. Reversal the contractile process is a strategy for the search of new drugs that could be used for the treatment of asthma. This work reports the semisynthesis, *ex vivo* relaxing evaluation and SAR studies of a series of 18 coumarins. The results pointed that the ether derivatives **1–3**, **7–9** and **13–15** showed the best activity ($E_{\max} = 100\%$), where compound **2** (42 μM) was the most potent, being 4-times more active than theophylline (positive control). The ether homologation (methyl, ethyl and propyl) in position 7 or positions 6 and 7 of coumarins lead to relaxing effect, meanwhile formation of esters generated less active compounds than ethers. The SAR analysis showed that it is necessary the presence of two small ether groups and the methyl group at position 4 (site 3) encourage biological activity through soft hydrophobic changes in the molecule, without drastically affecting the cLogP.

© 2014 Published by Elsevier Masson SAS.

Abbreviations: $(\text{CH}_3\text{CO})_2\text{O}$, acetic anhydride; μL , microliters; μM , micromolar; $\text{C}_4\text{H}_7\text{BrO}_2$, ethyl bromoacetate; CaCl_2 , calcium chloride; cAMP, cyclic adenosine monophosphate; CDCl_3 , Deuterated chloroform; cGMP, cyclic guanosine monophosphate; CH_3CN , acetonitrile; CO_2 , carbon dioxide; CRC, concentration–response curve; DMF, dimethylformamide; DMSO, dimethyl sulfoxide; EC_{50} , media effective concentration; EDTA, ethylenediaminetetraacetic acid; $\text{E}^+ - \text{MS} [\text{M}^+]$, electron impact–mass spectrometry; E_{\max} , maximum effect; Et_3N , triethylamine; g, gram; H, hour; H_2SO_4 , sulfuric acid; Hz, hertz; J, coupling constants; K_2CO_3 , potassium carbonate; KCl, potassium chloride; KH_2PO_4 , potassium phosphate monobasic; KI, potassium iodide; KOH, potassium hydroxide; Me_2SO_4 , dimethyl sulfate; MgSO_4 , magnesium sulfate; cLogP, partition coefficient calculated; mL, milliliters; mm, millimeters; Mp, melting point; NaCl, sodium chloride; NaHCO_3 , Sodium bicarbonate; NMR, nuclear magnetic resonance; O_2 , oxygen; Oct/wat, octanol–water mixture; ppm, parts per million; SM1, starting material 1; SM2, starting material 2; SM3, starting material 3; SAR, structure–activity relationship; SN_2 , bimolecular nucleophilic substitution; TLC, thin layer chromatography; TMS, tetramethylsilane; UV, ultra violet.

* Corresponding authors. Facultad de Farmacia, Avenida Universidad 1001, Col. Chamilpa, 62209 Cuernavaca, Morelos, Mexico.

E-mail addresses: gabriel.navarrete@uaem.mx (G. Navarrete-Vázquez), enoch@uaem.mx (S. Estrada-Soto).

¹ Taken from the Ph. D. thesis of Amanda Sánchez-Recillas.

² These authors contribute equally in current work.

<http://dx.doi.org/10.1016/j.ejmech.2014.03.029>

0223-5234/© 2014 Published by Elsevier Masson SAS.

1. Introduction

Asthma is a chronic inflammatory disorder of the airways. The chronic inflammation of airway is characterized by the hyperre-activity causing limited airflow (by bronchoconstriction, mucus plug and increased inflammation) when airways are exposed to allergens such as those from house dust mites, animals with fur, cockroaches, pollens and molds, occupational irritants, tobacco smoke, respiratory infections, exercise, chemical irritants and drugs [1]. These affect 300 million people worldwide, especially to child population [2]. In the first place, drug therapy is centered on counteracting bronchoconstriction and/or inflammation processes using β_2 -agonist and inhaled glucocorticoids, respectively. Besides, there are some other therapeutic alternatives as leukotriene receptor antagonist, phosphodiesterases inhibitors, anticholinergics and anti-IgE, which are indicated for the successful treatment of asthma. However, they are not completely effective in chronic treatment [1]. Plants, especially those with ethnopharmacological uses, have been the primary source for early drug discovery.

Furthermore, many bioactive compounds have been isolated from these or have served as a prototype to develop new molecules with therapeutic interest [3], e.g. coumarins that are phenolic compounds with a common structure of 2-*H*-1-benzopyran-2-one with multiple biological effects such as anti-inflammatory, anticoagulant, antibacterial, antifungal, antiviral, anticancer, antihypertensive, antitubercular, anticonvulsant, antiadipogenic, antihyperglycemic, antioxidant, and neuroprotective properties [4–6]. Therefore, the search for novel molecules based on coumarin scaffold with therapeutic activity represents pharmacological alternatives to treat prevalent diseases such as asthma.

2. Results and discussion

2.1. Chemistry

In this work was carried out the semisynthesis of 18 coumarins (1–18), on the basis of 6,7-dihydroxycoumarin (compounds 1–6), 7-hydroxycoumarin (compounds 7–12) and 4-methyl-7-hydroxycoumarin (compounds 13–18) through alkylation and esterification of hydroxyl groups in position 6, or 6 and 7 of coumarin structure as previously described (1–3) (Table 1). Compounds were obtained in discrete to moderate yields, and were purified by recrystallization. The chemical structures of the synthesized compounds were determined based on their spectral data (^1H , ^{13}C NMR and mass spectra $\text{MS}^+ \text{EI} [\text{M}^+]$).

2.2. Rat tracheal ring assay


All the compounds were evaluated [0.1–500 μM] on the contraction induced by carbachol (1 μM , muscarinic cholinergic agonist) in the trachea rat rings; and theophylline (phosphodiesterases inhibitor) was used as positive control. Table 2 shows values

of median effective concentration (EC_{50}), maximum effect (E_{max}) as well as calculated LogP for each compound (cLogP).

Esculetin (6,7-dihydroxycoumarin, **SM1**) is a *di*-hydroxylated coumarin, which has significant pharmacological effects such as anticoagulant, anti-inflammatory, vasoconstriction inhibitor, hepatoprotective, anti-obesity, hypolipidemic, and neuroprotective agent [7–12]. Compounds designed from **SM1** have great potential to show important pharmacological effects [4]. The most active compounds derived from **SM1** were *di*-ethers: (1) methoxy-, (2) ethoxy- and (3) propoxy-, which achieved 100% of relaxation and the CRC moved toward left with respect to **SM1** ($E_{\text{max}} = 48\%$) and theophylline ($E_{\text{max}} = 100\%$, $\text{EC}_{50} = 144 \mu\text{M}$) used as positive control (Fig. 1); this fact suggests that compounds were more potent than **SM1** and theophylline. Compounds 1 and 3 are equipotent ($\text{EC}_{50} = 80 \mu\text{M}$), and the compound 2 ($\text{EC}_{50} = 42 \mu\text{M}$) achieved the most potent tracheal relaxation of the entire series, which was 4-times more potent than theophylline. Compounds 4, 5 and 6 (CCR not shown) didn't showed significant relaxant effect on the contraction induced by carbachol.

Umbelliferone (7-hydroxycoumarin, **SM2**) is a *mono*-hydroxylated coumarin that also showed significant pharmacological effects such as antidiabetic, hypolipidemic, anti-inflammatory, anti-allergic, anti-oxidant, and bronchodilator [13–16]. This compound was previously isolated from plant species that are used in traditional medicine as anti-asthmatic [17]. Therefore, compounds designed from umbelliferone have great potential to show important pharmacological effects, including as antiasthmatic [4]. The *mono* and *di*-ether derivatives of **SM2** such as 7, 8 and 9 reached 100% of relaxation, but were less potent than the *di*-ethers, however their CCR were moved to the left compared than **SM2** (Fig. 2). Compound 9 was the most potent ($\text{EC}_{50} = 133 \mu\text{M}$) in this series, it is considered to be equipotent with theophylline. The ester derivatives 10, 11 and 12 didn't show significant relaxing effect ($E_{\text{max}} = <30\%$) on the contraction induced by carbachol.

Table 1
Physicochemical data of the semisynthetic coumarin derivatives.



Compound number	R ₁	R ₂	R ₃	Molecular weight (g/mol)	Melting point (°C)	Reaction time (h)	Unoptimized yield (%)	M.W. EI MS: (m/z) [M] ⁺
SM1	–H	–OH	–OH	178	271.0–273.0	–	–	178
1	–H	–OMe	–OMe	206	128.0–130.0	80	38	206
2	–H	–OEt	–OEt	234	105.5–106.5	48	54	234
3	–H	–OPr	–OPr	262	79.5–81.5	48	85	262
4	–H	–OAc	–OAc	262	127.6–130.4	48	78	178
5	–H	–OCOPh	–OCOPh	386	185.1–186.6	48	85	386
6	–H	–OCH ₂ COOEt	–OCH ₂ COOEt	350	107.0–108.8	6	91	350
SM2	–H	–H	–OH	162	230.0	–	–	162
7	–H	–H	–OMe	176	117.8–119.8	24	95	176
8	–H	–H	–OEt	190	86.7–88.7	60	46	190
9	–H	–H	–OPr	204	62.6–63.9	36	27	204
10	–H	–H	–OAc	204	133.5–135.0	0.5	90	204
11	–H	–H	–OCOPh	266	158.0–159.3	12	78	266
12	–H	–H	–OCH ₂ COOEt	248	112.2–114.2	6	96	248
SM3	–Me	–H	–OH	176	190.0–192.0	–	–	176
13	–Me	–H	–OMe	190	158.6–161.7	48	77	190
14	–Me	–H	–OEt	204	108.2–110.5	80	37	204
15	–Me	–H	–OPr	218	74.4–75.2	240	96	218
16	–Me	–H	–OAc	218	152.5–153.5	0.5	92	219
17	–Me	–H	–OCOPh	280	161.5–163.5	12	86	280
18	–Me	–H	–OCH ₂ COOEt	262	100.1–103.1	8	71	262

SM: Starting Materials, [M]⁺ = molecular ion found.

Table 2

Ex vivo pharmacological parameters of the relaxant effect of coumarin derivatives used in the SAR study.






















Compound number	Structure	E_{\max} (%)	EC_{50} (μ M)	miLogP
SM1		47.9	NS	1.021
1		100	80	1.636
2		100	42	2.388
3		100	89	3.394
4		77	231	0.627
5		12	NS	5.259
6		33	NS	2.113
SM2		67	449	1.511
7		100	244	2.046
8		100	245	2.422
9		100	133	2.925
10		16	NS	1.542
11		26	NS	3.858
12		31	NS	2.285
SM3		90	260	1.887
13		100	230	2.423
14		100	80	2.799
15		100	267	3.302
16		62	360	1.918

Table 2 (continued)

Compound number	Structure	E_{\max} (%)	EC_{50} (μ M)	miLogP
17		34	NS	4.234
18		70	200	2.661

E_{\max} : maximum effect; EC_{50} : median effective concentration; RM: Raw materials; NS: Not shown; given that $E_{\max} < 40\%$.

4-Methylumbelliferone (**SM3**) is a coumarin that has demonstrated pharmacological effects as analgesic, anti-arthritis, anti-inflammatory, antipyretic, antibacterial, anti-viral, anti-cancer, among others [18]. However, it has not been demonstrated the possible relaxing effect of the tracheal smooth muscle. **SM3** showed significant relaxing effect ($E_{\max} = 90\%$), and the ether derivatives **13**, **14** and **15** showed 100% of relaxation. Compound **14** ($EC_{50} = 80 \mu\text{M}$) was the most potent in this series. The CCR of **14** is shifted to the left compared with theophylline (Fig. 3). Once again, the ester derivatives **16**, **17** and **18** of **SM3** also did not showed significant relaxant effect.

These findings suggest that increasing in the lipophilic chain in position 6 and/or 7 of the coumarin skeleton increases the relaxing effect in rat tracheal rings, while reducing the lipophilic chain the effect reduces too. As described above, one of the strategies to treat asthma is to reduce the bronchoconstriction. The main target could be to generate relaxation of the smooth muscle cells of the airway by the increasing of cyclic nucleotide second messengers (cAMP and cGMP), decrease of intracellular calcium (calcium channel blockers), the inhibition of excitatory response (anti-cholinergic, antihistamines, anti-leukotriens) or induce relaxing direct response (β -agonists or phosphodiesterases inhibition) [19]. The coumarin ether derivatives may act by inhibition of cyclic nucleotide phosphodiesterases that generate cAMP and cGMP increasing, as established by Hout and Payá [20] and Billington et al. [21]. Also, can increase the intracellular concentration of cAMP by activation of β_2 -adrenergic receptors or prostaglandins- E_2 production [19], with subsequent decrease of the influx of calcium through the blockade of calcium channels of membrane [22], as well as blocking




Fig. 1. Concentration–response curves of ethers compounds **1–3** and **SM1** on trachea rings pre-contracted with carbachol [1 μ M]. All results are expressed as the mean \pm S.E.M of six experiments (* $p < 0.05$).




Fig. 2. Concentration–response curves of ethers compounds 7–9 and SM2 on trachea rings pre-contracted with carbachol [1 μ M]. All results are expressed as the mean \pm S.E.M of six experiments (* p < 0.05).

of calcium channels from intracellular, generating the decrease in intracellular calcium concentrations [23,24]. Meurs et al. [25] suggest that the importance of muscarinic receptors not only involves the blockage of the airway, but also have an important regulatory role in the function of β_2 -adrenergic receptors agonists and inflammation; thus, the coumarin derivatives can act through a muscarinic antagonism [26]. It is worth mentioning that previous studies have shown that the compound 1 has significant vaso-relaxant [27] and anti-allergic [28] effects. Finally, the underlying mechanism of relaxant action and the possible anti-inflammatory activity of the most active compounds 1, 2, 3, 9 and 14 are current studying in order to develop new potential drugs for the treatment of asthma [24,29].

2.3. Structure–activity relationship (SAR) of coumarin derivatives

For SAR analysis it was used descriptors of LogP values (Table 2) calculated with different programs and after that were averaged




Fig. 3. Concentration–response curves of ethers compounds 13–15 and SM3 on trachea rings pre-contracted with carbachol [1 μ M]. All results are expressed as the mean \pm S.E.M of six experiments (* p < 0.05).




Fig. 4. Pharmacophoric pattern based on experimental results.

and grouped in the ALOGPS 2.1 software available online [30,31]. In addition, the experimental EC_{50} and E_{max} values from relaxant effect were considered. SM1 and SM2 bear hydroxyl groups (OH) in position 6 and 7 or 7, respectively, and it seems that these polar substituents did not contribute with the relaxing effect in the trachea, while the SM3, with a hydroxyl group in position C-7 and a small lipophilic group ($-CH_3$) in position C-4, increased the relaxant effect. Homologated ether derivatives (with a maximum of three carbons) in the position C-6 and C-7 of the coumarins, drastically increase relaxant effect generating the most potent compounds as 1, 2 and 3. The ether formation only in position C-7 with and without a methyl group in C-4 also increases the relaxant effect; however, all of them are less potent than 1, 2 and 3, which indicates that is necessary to add lipophilic groups such as di-ether derivatives to improve the relaxant effect. Ester derivatives (acetyl and benzoyl) reduced relaxant effect. SAR analysis revealed the minimal stereo-electronic requirements for good relaxation activity: 1) Positions C-6 and C-7 substituted with homologous aliphatic ether chains (1–3 carbon atoms, preferable two) reflect possible steric and lipophilic molecular recognition from the cavities in the active site. Strong improvements of ligand affinity for many therapeutic targets are frequently accompanied by modest lipophilicity increases [32]. 2) Sometimes, a methyl group with its lipophilic surface well included into a protein hydrophobic pocket is expected to provide 1.5 kcal/mol binding energy and so give up to a 10-fold improvement in binding energy [33]. In this case, position C-4 of the coumarin replaced with a methyl group (compound 14), improved the activity 3-fold versus compound 8, but it was not as active as the most potent compound (2).

Based on the most active molecules treated in this study (compounds 2 and 14), we examine the effect of different substituents in the molecular scaffold of coumarin derivatives. The construction of pharmacophoric model (Fig. 4) and a proposed new molecule designed (Fig. 5) was based on experimental results and is




Fig. 5. New coumarin derivative molecule designed based on the data generated in this work.

describing the main chemical features shared by the most active coumarin derivatives. A chemical inspection of molecular structure suggest an incorporation of methyl group at position 4, as well as ethoxy substitutions at positions 6 and 7. The three dimensional display was built with the program DSV3.5. [34].

3. Conclusions

The skeleton of 2*H*-1-benzopyran-2-one (coumarin) represents a remarkable scaffold with interesting airway relaxant properties to develop new therapeutic alternatives that are useful in the treatment of asthma. Compounds 2, 9 and 14, from each series, respectively, showed the best activity, being compound 2 the most potent of all of three series. The SAR analysis shown that the presence of two small ether groups (6 and/or 7 position) and the methyl group at position 4, increases biological activity through soft changes in the hydrophobic characteristic of the molecule, since it doesn't drastically affects the LogP. Last should be between 2.0 and 2.7 and/or less than 3, because after that value the hydrophobic molecule would lose effectiveness and potency.

4. Experimental

4.1. Chemistry

All chemicals were ACS grade and all starting materials and reagents were obtained commercially from Sigma–Aldrich and were used as received. Melting points were determined on an EZ-Melt MPA120 automated melting point apparatus from Stanford Research Systems and are uncorrected. TLC monitored reactions on 1.5 × 3.0 cm pre-coated silica gel 60 F₂₅₄ plates (E. Merck KGaA, Darmstadt, Germany) and visualized with 254-nm UV light. The reactions that lasted for more than 24 h were kept in refrigerator for overnight.

NMR studies were carried out with a Varian Inova 400 instrument. Chemical shifts (δ_{H} , δ_{C}) and coupling constants values (*J*) are given in ppm and Hz, respectively. The following abbreviations for signal multiplicities are represented by s (singlet), d (doublet), t (triplet), q (quartet) and m (multiplet). Standard reference was used: TMS (δ_{H} = 0, δ_{C} = 0) in CDCl₃. Mass spectra were recorded on a Jeol JMS-700 equipment (JEOL USA Inc., Peabody, MA, USA).

4.1.1. General method of semisynthesis of compounds 1–3, 7–9 and 13–15

Compounds were prepared using bimolecular nucleophilic substitution (*S*_N2) reaction, starting from 6,7-dihydroxycoumarin (**SM1**), 7-hydroxycoumarin (**SM2**) or 7-hydroxy-4-methylcoumarin (**SM3**) as starting materials (**SM**), polar aprotic solvents [acetone, acetonitrile (CH₃CN), dimethylformamide (DMF)] and potassium carbonate (K₂CO₃) or potassium hydroxide (KOH) as a base. All reactions were carried out with moderate heating (<40 °C). The crude products were washed with cold water, filtered, dried and purified according to the procedures reported [35].

4.1.2. Preparation of 1, 7 and 13 (Scheme 1a)

0.4 g of **SM1** (2.2 mmol), **SM2** (2.4 mmol) and **SM3** (2.2 mmol), respectively, were dissolved with CH₃CN (2.0 mL). After that, solid KOH (1.5 or 3 equivalents) was added, and stirred during thirty minutes. 2.1 equivalents of dimethyl sulfate (Me₂SO₄) were added to the mixture and heating for 48 h at 40 °C. Finally, when reaction was completed (monitored by TLC analysis), the solid was filtered off and dried to afford the corresponding compounds **1** (6,7-dimethoxy-2*H*-chromen-2-one), **7** (7-methoxy-2*H*-chromen-2-one) and **13** (7-methoxy-4-methyl-2*H*-chromen-2-one), respectively.

4.1.2.1. 6,7-Dimethoxy-2*H*-chromen-2-one (1). Pale yellow powder, 60% yield, mp: 128.0–130.0 °C, recrystallized from 100% ethanol. ¹H NMR (CDCl₃) δ : 3.93 (3H, s, CH₃), 3.95 (3H, s, CH₃), 6.28 (1H, d, *J* = 9.6 Hz), 6.83 (1H, s), 6.87 (1H, s), 7.64 (1H, d, *J* = 9.6 Hz); ¹³C NMR (50 MHz, CDCl₃): δ_{C} 56.2 (CH₃), 100.1 (CH), 108.1 (CH), 111.5 (C), 113.5 (CH), 143.4 (CH), 146.4 (C), 150.1 (C), 152.9 (C), 161.4 (C).

4.1.2.2. 7-Methoxy-2*H*-chromen-2-one (7). White crystals, 95% yield, mp: 117.8–119.8 °C, recrystallized from 100% methanol. ¹H NMR (CDCl₃) δ : 3.88 (3H, s), 6.25 (1H, d, *J* = 9.6 Hz), 6.86 (1H, d, *J* = 1.6 Hz), 7.63 (2H, d, *J* = 9.6 Hz), 7.37 (1H, dd, *J* = 9.6 Hz, 1.6 Hz); ¹³C NMR (200 MHz, CDCl₃): δ_{C} 55.9 (CH₃), 101.0 (CH), 112.7 (CH), 113.2 (CH), 113.2 (C), 128.9 (CH), 143.5 (CH), 160.0 (C), 161.2 (C), 163.0 (C).

4.1.2.3. 7-Methoxy-4-methyl-2*H*-chromen-2-one (13). White powder, 77% yield, mp: 158.6–161.7 °C, recrystallized from 100% ethanol. ¹H NMR (CDCl₃) δ : 2.40 (3H, s), 3.88 (3H, s), 6.14 (1H, s), 6.82 (1H, d, *J* = 2.6 Hz), 6.86 (1H, dd, *J* = 8.8, 2.6 Hz), 7.50 (1H, d, *J* = 8.8 Hz); ¹³C NMR (200 MHz, CDCl₃): δ_{C} 18.9 (CH₃), 55.9 (CH₃), 101.1 (CH), 112.0 (CH), 112.5 (CH), 113.8 (C), 125.7 (CH), 152.7 (C), 155.4 (C), 161.4 (C), 162.8 (C).

4.1.3. Preparation of 2, 8 and 14 (Scheme 1b)

0.4 g of **SM1** (2.2 mmol), **SM2** (2.4 mmol) and **SM3** (2.2 mmol), respectively, were dissolved with 2 mL of DMF (compound **2**) or acetone (compound **8** and **14**). After that, solid K₂CO₃ (1.9 or 3.8 equivalents) were add, and stirred during thirty minutes. 2.2 equivalents of ethyl iodide and potassium iodide (as catalyst) were added to the mixture and heating for 2, 2.5 and 5 days at 40 °C, respectively. Finally, when reaction was completed (monitored by TLC analysis), the solid was filtered off and dried to afford the corresponding compounds **2** (6,7-diethoxy-2*H*-chromen-2-one), **8** (7-ethoxy-2*H*-chromen-2-one) and **14** (7-ethoxy-4-methyl-2*H*-chromen-2-one).


4.1.3.1. 6,7-Diethoxy-2*H*-chromen-2-one (2). Yellow powder, 54% yield, mp: 105.5–106.5 °C, recrystallized from 100% ethanol. ¹H NMR (CDCl₃) δ : 1.48 (3H, t, *J* = 7.2 Hz), 1.51 (3H, t, *J* = 7.2 Hz), 4.10 (2H, q, *J* = 7.2 Hz), 4.15 (2H, q, *J* = 7.2 Hz), 6.26 (1H, d, *J* = 9.6 Hz), 6.82 (1H, s), 6.87 (1H, s), 7.60 (1H, d, *J* = 9.6 Hz); ¹³C NMR (400 MHz, CDCl₃): δ_{C} 14.6 (CH₂), 14.9 (CH₂), 65.0 (CH₂), 65.4 (CH₂), 101.2 (CH), 110.3 (CH), 111.5 (C), 113.4 (CH), 143.6 (CH), 145.9 (C), 150.2 (C), 152.9 (C), 161.7 (C).

4.1.3.2. 7-Ethoxy-2*H*-chromen-2-one (8). White powder, 46% yield, mp: 86.7–88.7 °C, recrystallized from 100% ethanol. ¹H NMR (CDCl₃) δ : 1.46 (3H, t, *J* = 7.0 Hz), 4.10 (2H, q, *J* = 7.0 Hz), 6.24 (1H, d, *J* = 9.4 Hz), 6.81 (1H, s), 7.34 (1H, d, *J* = 8.8 Hz), 7.63 (1H, d, *J* = 9.4 Hz), 7.82 (1H, dd, *J* = 8.8, 2.4 Hz); ¹³C NMR (200 MHz, CDCl₃): δ_{C} 14.8 (CH₃), 64.4 (CH₂), 101.5 (CH), 112.5 (C), 113.1 (CH), 113.1 (CH), 128.8 (CH), 143.6 (CH), 156.0 (C), 161.4 (C), 162.3 (C).

4.1.3.3. 7-Ethoxy-4-methyl-2*H*-chromen-2-one (14). White powder, 37% yield, mp: 108.2–110.5 °C, recrystallized from 100% ethanol. ¹H NMR (CDCl₃) δ : 1.42 (3H, t, *J* = 7.2 Hz), 2.36 (3H, d, *J* = 1.2 Hz), 4.06 (2H, q, *J* = 7.2 Hz), 6.09 (1H, s), 6.76 (1H, d, *J* = 2.8 Hz), 6.82 (1H, dd, *J* = 8.8, 2.8 Hz), 7.45 (1H, d, *J* = 8.8 Hz); ¹³C NMR (400 MHz, CDCl₃): δ_{C} 14.5 (CH₃), 18.7 (CH₃), 64.1 (CH₂), 101.3 (CH), 111.8 (CH), 112.6 (CH), 113.5 (C), 125.5 (CH), 152.7 (C), 155.2 (C), 161.5 (C), 162.0 (C).

4.1.4. Preparation of 3, 9 and 15 (Scheme 1c)

0.4 g of **SM1** (2.2 mmol), **SM2** (2.4 mmol) and **SM3** (2.2 mmol), respectively, were dissolved with 2 mL of acetone (for compound **9** and **15**) and DMF (for compound **3**). After that, solid K₂CO₃ (4 molar



Scheme 1. Synthesis of homologous coumarin derivatives: methyl (a), ethyl (b), propyl (c), acetyl (d), benzoyl and (e) Ethoxy-2-oxoethyl (f). Reagents and conditions: (i) CH_3CN , KOH , Me_2SO_4 /reflux, (ii) DMF or acetone, K_2CO_3 , ethyl iodide, KI /reflux, (iii) DMF or acetone, K_2CO_3 , *n*-propyl bromide, Et_3N or KI /reflux, (iv) acetic anhydride, H_2SO_4 , Et_3N , (v) benzoyl chloride, Et_3N (vi), acetone, K_2CO_3 , ethyl bromoacetate.

equivalent) was added and stirred during thirty minutes. Then 3 equivalents of triethylamine (Et₃N) and 3 equivalents of *n*-propyl bromide were added. All of three reactions were heating for 2, 2.5 and 5 days at 40 °C, respectively. After reactions were completed (analyzed by TLC), the solid was filtered off and dried to afford the corresponding compounds **3** (6,7-dipropoxy-2H-chromen-2-one), **9** (7-propoxy-2H-chromen-2-one) and **15** (4-methyl-7-propoxy-2H-chromen-2-one).

4.1.4.1. 6,7-Dipropoxy-2H-chromen-2-one (3). Beige powder, 85% yield, mp: 79.2–81.8 °C, recrystallized from 100% methanol. ¹H NMR (CDCl₃) δ: 1.06 (3H, t, *J* = 7.6), 1.08 (3H, t, *J* = 7.6), 1.85 (2H, q, *J* = 7.2 Hz), 1.90 (2H, q, *J* = 7.2 Hz), 3.98 (2H, t, *J* = 6.4 Hz), 4.01 (2H, t, *J* = 6.4 Hz), 6.25 (1H, d, *J* = 9.6 Hz), 6.81 (1H, s), 6.87 (1H, s), 7.60 (1H, d, *J* = 9.6 Hz); ¹³C NMR (400 MHz, CDCl₃): δ_q 10.6 (CH₃), 10.6 (CH₃), 22.4 (CH₂), 22.5 (CH₂), 70.9 (CH₂), 71.6 (CH₂), 101.1 (CH), 110.8 (CH), 111.5 (C), 113.3 (CH), 143.6 (CH), 146.3 (C), 150.3 (C), 153.4 (C), 161.7 (C).

4.1.4.2. 7-Propoxy-2H-chromen-2-one (9). White powder, 27% yield, mp: 62.6–63.9 °C, recrystallized from 1:1 methanol: ethanol mixture. ¹H NMR (CDCl₃) δ: 1.05 (3H, t, *J* = 7.6 Hz), 1.83 (2H, q, *J* = 7.2 Hz), 3.97 (2H, t, *J* = 6.4 Hz), 6.23 (1H, d, *J* = 9.6 Hz), 6.80 (1H, d, *J* = 2.4 Hz), 6.84 (1H, d, *J* = 2.4 Hz), 7.36 (1H, d, *J* = 8.4 Hz), 7.63 (1H, d, *J* = 9.6 Hz); ¹³C NMR (100 MHz, CDCl₃): δ_q 10.6 (CH₃), 22.5 (CH₂), 70.3 (CH₂), 101.5 (CH), 112.5 (CH), 113.1 (C), 113.1 (CH), 128.9 (CH), 143.7 (CH), 156.9 (C), 161.5 (C), 162.6 (C).

4.1.4.3. 4-Methyl-7-propoxy-2H-chromen-2-one (15). White crystals, 96% yield, mp: 74.4–75.2 °C, recrystallized from 100% methanol. ¹H NMR (CDCl₃) δ: 1.03 (3H, t, *J* = 7.6 Hz), 1.81 (2H, m), 1.83 (2H, q, *J* = 7.2 Hz), 2.36 (3H, d, *J* = 1.2 Hz), 3.94 (2H, t, *J* = 6.4 Hz), 6.23 (1H, s), 6.82 (1H, dd, *J* = 2.4, 2.4 Hz), 6.75 (1H, d, *J* = 2.4 Hz), 7.44 (1H, d, *J* = 8.8 Hz); ¹³C NMR (400 MHz, CDCl₃): δ_q 10.41 (CH₃), 18.7 (CH₃), 22.3 (CH₂), 70.0 (CH₂), 101.3 (CH), 111.8 (CH), 112.6 (CH), 113.4 (C), 125.4 (CH), 152.5 (C), 155.3 (C), 161.3 (C), 162.2 (C).

4.1.5. General methods of synthesis of compounds **4–5**, **10–11** and **16–17**

Esterification of **SM1** (2.2 mmol), **SM2** (2.4 mmol) and **SM3** (2.2 mmol) were carried out with acetic anhydride [(CH₃CO)₂O] and sulfuric acid as catalyst, or benzoyl chloride and Et₃N. All reactions were carried out in agitation at room temperature. The crude reactions were washed with cold water, filtered, dried and purified according to the procedures reported [35].

4.1.6. Preparation of **4**, **10** and **16** (Scheme 1d)

0.4 g of **SM1** (2.2 mmol), **SM2** (2.4 mmol) and **SM3** (2.2 mmol), respectively, were stirred with 4 molar equivalents of acetic anhydride and two drops of H₂SO₄ (as catalyst) under ice bath. After that, 2.5 molar equivalents of Et₃N were added to the mixture and agitated for 2 days, 10 min and 30 min, respectively, at room temperature. After reactions were completed (analyzed by TLC), the solid was filtered off and dried to afford the corresponding compounds **4** (2-oxo-2H-chromene-6,7-diyl diacetate), **10** (2-oxo-2H-chromen-7-yl acetate) and **16** (4-methyl-2-oxo-2H-chromen-7-yl acetate), respectively.

4.1.6.1. 2-Oxo-2H-chromene-6,7-diyl diacetate (4). Gray powder, 78% yield, mp: 127.6–130.4 °C, recrystallized from 100% ethanol. ¹H NMR (CDCl₃) δ: 2.32 (3H, s), 2.34 (3H, s), 6.43 (1H, d, *J* = 9.6 Hz), 7.26 (1H, s), 7.35 (1H, s), 7.64 (1H, d, *J* = 9.6 Hz); ¹³C NMR (200 MHz, CDCl₃): δ_q 20.8 (CH₃), 112.5 (CH), 117.0 (C), 117.1 (CH), 121.8 (CH), 138.9 (C), 142.5 (CH), 144.9 (C), 151.8 (C), 160.0 (C), 167.7 (C).

4.1.6.2. 2-Oxo-2H-chromen-7-yl acetate (10). White powder, 90% yield, mp: 133.5–135.0 °C, recrystallized from 100% ethanol. ¹H NMR (CDCl₃) δ: 2.34 (3H, d, *J* = 2.4 Hz), 6.40 (1H, d, *J* = 10.2 Hz), 7.05 (1H, dd, *J* = 8.4, 2.2 Hz), 7.12 (1H, d, *J* = 2.2 Hz), 7.49 (1H, d, *J* = 8.4 Hz), 7.70 (1H, d, *J* = 10.2 Hz); ¹³C NMR (50 MHz, CDCl₃): δ_q 20.4 (CH₃), 110.6 (CH), 116.2 (CH), 116.8 (C), 118.5 (CH), 128.7 (CH), 143.0 (CH), 153.3 (C), 154.8 (C), 160.4 (C), 168.8 (C).

4.1.6.3. 4-Methyl-2-oxo-2H-chromen-7-yl acetate (16). White powder, 92% yield, mp: 152.5–153.5 °C, recrystallized from ethanol. ¹H NMR (CDCl₃) δ: 2.34 (3H, s), 2.43 (3H, d, *J* = 1.2 Hz), 6.27 (1H, d, *J* = 1.2 Hz), 7.06 (1H, d, *J* = 1.8 Hz), 7.11 (1H, dd, *J* = 8.4, 1.8 Hz), 7.61 (1H, d, *J* = 8.4 Hz); ¹³C NMR (200 MHz, CDCl₃): δ_q 18.9 (CH₃), 21.4 (CH₃), 110.6 (CH), 114.7 (CH), 118.0 (C), 118.2 (CH), 125.5 (CH), 152.0 (C), 153.2 (C), 154.3 (C), 160.5 (C), 168.8 (C).

4.1.7. Preparation of **5**, **11** and **17** (Scheme 1e)

0.4 g of **SM1** (2.2 mmol), **SM2** (2.4 mmol) and **SM3** (2.2 mmol), respectively, were stirred in 2 mL of CH₂Cl₂. After that, 2.5 molar equivalents of Et₃N, and 5 molar equivalents of benzoyl chloride were added to the mixture. Reaction was agitated for 2 days and 12 h for compounds **5**, **11** and **17**, respectively. After reactions were completed (analyzed by TLC), the solid was filtered off and dried to afford the corresponding compounds **5** (2-oxo-2H-chromen-7-yl benzoate), **11** (2-oxo-2H-chromene-7-yl benzoate) **17**. (4-methyl-2-oxo-2H-chromene-7-yl benzoate) **17**.

4.1.7.1. 2-Oxo-2H-chromene-6,7-diyl dibenzoate (5). Translucent powder, 82% yield, mp: 185.1–186.6 °C, recrystallized from 100% acetonitrile. ¹H NMR (CDCl₃) δ: 6.48 (1H, d, *J* = 9.6 Hz), 7.26 (1H, s), 7.39 (4H, dd, *J* = 8.0, 8.0 Hz), 7.44 (1H, s), 7.56 (2H, m), 7.72 (1H, d, *J* = 9.6 Hz), 8.05 (4H, d, *J* = 7.6 Hz); ¹³C NMR (200 MHz, CDCl₃): δ_q 113.2 (CH), 117.7 (C), 117.7 (CH), 121.6 (CH), 128.2 (C), 129.4 (CH), 131.1 (CH), 134.8 (CH), 134.9 (CH), 139.4 (C), 143.2 (CH), 146.7 (C), 152.7 (C), 160.8 (C), 164.9 (C).

4.1.7.2. 2-Oxo-2H-chromen-7-yl benzoate (11). White powder, 78% yield, mp: 158.0–159.3 °C, recrystallized from 100% methanol. ¹H NMR (CDCl₃) δ: 6.42 (1H, d, *J* = 9.6 Hz), 7.19 (1H, dd, *J* = 8.4, 2.2 Hz), 7.53 (1H, d, *J* = 2.2 Hz), 7.48–7.60 (3H, m), 7.66 (1H, d, *J* = 8.4 Hz), 7.72 (1H, d, *J* = 9.6 Hz), 8.21 (2H, d, *J* = 7.6 Hz); ¹³C NMR (200 MHz, CDCl₃): δ_q 110.8 (CH), 116.3 (CH), 116.9 (C), 118.7 (CH), 128.8 (CH), 128.9 (CH), 130.4 (CH), 134.2 (C), 134.2 (CH), 143.0 (CH), 153.6 (C), 154.9 (C), 160.4 (C), 164.6 (C).

4.1.7.3. 4-Methyl-2-oxo-2H-chromen-7-yl benzoate (17). White powder, 86% yield, mp: 161.5–163.5 °C, recrystallized from 100% ethanol. ¹H NMR (CDCl₃) δ: 2.46 (3H, d, *J* = 1.2 Hz), 6.30 (1H, d, *J* = 1.2 Hz), 7.21 (1H, dd, *J* = 8.4, 1.8 Hz), 7.25 (1H, d, *J* = 1.8 Hz), 7.48–7.50 (3H, m), 7.67 (1H, d, *J* = 8.4 Hz), 8.22 (2H, dd, *J* = 8.4, 1.4 Hz); ¹³C NMR (200 MHz, CDCl₃): δ_q 19.0 (CH₃), 110.8 (CH), 114.7 (CH), 119.0 (C), 118.4 (CH), 125.6 (CH), 128.9 (CH), 130.4 (CH), 134.2 (CH), 152.0 (C), 153.5 (C), 154.4 (C), 160.6 (C), 164.6 (C), 190.0 (C).

4.1.8. General methods of synthesis of compounds **6**, **12** and **18**

Reactions were carried out by etherification of **SM1** (2.2 mmol), **SM2** (2.4 mmol) and **SM3** (2.2 mmol) with ethyl bromoacetate (C₄H₇BrO₂), K₂CO₃, and acetone as solvent. The mixture was stirred at room temperature. The crude products were washed with cold water, filtered, dried and purified according to the procedures reported [35].

4.1.9. Preparation of **6**, **12** and **18** (Scheme 1f)

0.4 g of **SM1** (2.2 mmol), **SM2** (2.4 mmol) and **SM3** (2.2 mmol), respectively, were dissolved in acetone (2.0 mL) and 1.75 or 3.5

molar equivalents of K_2CO_3 was added, and stirred during thirty min. After that, it was added drop wise 1.75 molar equivalents of ethyl bromoacetate. The mixture was reacted at room temperature during 6 h for compounds **6** and **12**, and 8 h for **18**. After reactions were completed (analyzed by TLC), the solid was filtered off and dried to afford the corresponding compounds **6** ethyl {[6-(2-ethoxy-2-oxoethoxy)-2-oxo-2H-chromen-7-yl]oxy}acetate, **12** [ethyl 2-(2-oxo-2H-chromen-7-yloxy)acetate] and **18** [ethyl 2-(4-methyl-2-oxo-2H-chromen-7-yloxy)acetate].

4.1.9.1. Ethyl {[6-(2-ethoxy-2-oxoethoxy)-2-oxo-2H-chromen-7-yl]oxy}acetate (6**).** White powder, 91% yield, mp: 107.0–108.8 °C, recrystallized from 100% ethanol. 1H NMR ($CDCl_3$) δ : 1.30 (3H, t, $J = 7.0$ Hz), 1.32 (3H, t, $J = 7.0$ Hz), 4.27 (2H, q, $J = 7.0, 3.4$ Hz), 4.28 (2H, q, $J = 7.0, 3.4$ Hz), 4.75 (4H, d, $J = 7.6$ Hz), 6.30 (1H, d, $J = 9.6$ Hz), 6.76 (1H, s), 7.01 (1H, s), 7.59 (1H, d, $J = 9.6$ Hz); ^{13}C NMR (200 MHz, $CDCl_3$): δ 14.4 (CH_3), 61.6 (CH_2), 61.9 (CH_2), 66.2 (CH_2), 67.6 (CH_2), 102.4 (CH), 112.7 (C), 114.2 (CH), 114.6 (CH), 143.1 (CH), 144.9 (C), 150.5 (C), 151.9 (C), 161.0 (C), 167.8 (C), 168.8 (C).

4.1.9.2. Ethyl 2-(2-oxo-2H-chromen-7-yloxy)acetate (12**).** Yellow powder, 96% yield, mp: 112.2–114.4 °C, recrystallized from 100% ethanol. 1H NMR ($CDCl_3$) δ : 1.32 (3H, t, $J = 7.0$ Hz), 4.29 (2H, q, $J = 7.0$ Hz), 4.68 (2H, s), 6.28 (1H, d, $J = 9.6$ Hz), 6.78 (1H, d, $J = 2.2$ Hz), 6.90 (1H, dd, $J = 8.4, 2.2$ Hz), 7.40 (1H, d, $J = 8.4$ Hz), 7.64 (1H, d, $J = 9.6$ Hz); ^{13}C NMR (200 MHz, Acetone- d_6): δ 14.4 (CH_3), 61.9 (CH_2), 65.6 (CH_2), 101.9 (CH), 113.0 (CH), 113.5 (C), 113.9 (CH), 129.1 (CH), 143.3 (CH), 155.8 (C), 161.0 (C), 168.0 (C).

4.1.9.3. Ethyl 2-(4-methyl-2-oxo-2H-chromen-7-yloxy)acetate (18**).** White crystals, 71% yield, mp: 100.1–103.2 °C, recrystallized from 100% ethanol. 1H NMR ($CDCl_3$) δ : 1.29 (3H, t, $J = 7.2$ Hz), 2.37 (3H, d, $J = 1.2$ Hz), 4.25 (2H, q, $J = 7.2$ Hz), 4.65 (2H, s), 6.13 (1H, q, 1.2 Hz), 6.75 (1H, d, $J = 2.8$ Hz), 6.88 (1H, dd, $J = 8.8, 2.8$ Hz), 7.49 (1H, d, $J = 8.8$ Hz); ^{13}C NMR (400 MHz, $CDCl_3$): δ 14.1 (CH_3), 18.6 (CH_3), 61.7 (CH_2), 65.3 (CH_2), 101.7 (CH), 112.5 (CH), 112.5 (C), 114.4 (CH), 125.7 (CH), 152.3 (C), 155.0 (C), 160.6 (C), 161.0 (C), 167.9 (C).

4.2. Pharmacological evaluation

4.2.1. Chemicals and drugs

Carbamylcholine (carbachol), theophylline, dimethyl sulfoxide (DMSO) and ethyl ether were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA).

4.2.2. Animals

Healthy male Wistar rats (250–300 g) were used and maintained under standard laboratory conditions with free access to food and water. All animal procedures were conducted in accordance with our Federal Regulations for Animal Experimentation and Care (SAGARPA, NOM-062-ZOO-1999, México), and approved by the Institutional Animal Care and Use Committee based on US National Institute of Health publication (No. 85-23, revised 1985). All experiments were carried out using six animals per group. Animals used were euthanized by exposure to ethyl ether and cervical dislocation.

4.2.3. Rat trachea ring assay

A previous protocol was used [36]. The trachea was dissected and cleaned out of connective tissue and mucus, and immediately was cut into 4–5 mm length rings (each containing 2–3 cartilaginous rings). Then, tissue segments were mounted in stainless steel hooks, under optimal tension of 2 g, in 10 mL organ baths containing warmed (37 °C) and oxygenated (O_2/CO_2 , 95:5) Krebs solution (composition, mM: NaCl, 118; KCl, 4.7; $CaCl_2$, 2.5; $MgSO_4$, 1.2;

KH_2PO_4 , 1.2; $NaHCO_3$, 25.0; EDTA, 0.026 and glucose, 11.1, pH 7.4). Changes in tension were recorded by Grass-FT03 forced transducers (Astromed, West Warwick, RI, USA) connected to a MP100 analyzer (BIOPAC Instruments, Santa Barbara, CA, USA) as previously described. After equilibration, rings were contracted by carbachol [1 μM] and washed every 40 min for 2 h. After contraction with carbachol, the test samples (organics extracts, vehicle and positive control) were added to the bath in a volume of 100 μL ; then cumulative concentration–response curves were obtained for each ring (1–500 μM). The relaxant effect of extracts and positive control (theophylline, an inhibitor of phosphodiesterase; 1.67–550 μM) were determined by comparing the muscular tone of the contraction before and after addition of the test materials. Muscular tone was calculated from the tracings, using Acknowledge software (Biopac®).

4.3. Theoretical evaluation of lipophilicity

For a better understanding of the overall properties of the described compounds, the lipophilicity values were estimated through theoretical determination with $mLogP$ (expressed as the oct/wat) using the Molinspiration calculation program [37,38], also were calculated with different programs, and after that were averaged and grouped in the ALOGPS 2.1 software available online [30,31].

4.4. Data analysis

Data are expressed as mean of six experiments \pm standard error of mean (SEM). Concentration responses curves (CRC) were plotted and experimental data of the CRC were adjusted by the nonlinear, curve-fitting program Microcal TM origin 8.0 (Microcal Software Inc., USA). Significance was evaluated using the Student's t test. Values of $*p < 0.05$ imply significance of the pharmacological effects in the experiments.

Acknowledgments

This study was supported by Consejo Nacional de Ciencia y Tecnología (CONACYT) Proyecto de Ciencia Básica 2011-01 (167044) and Fellowship grant (298553) for the Ph.D studies of A. Sánchez-Recillas.

Appendix A. Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.ejmech.2014.03.029>.

References

- [1] <http://ginasthma.org/>.
- [2] <http://www.who.int/en/>.
- [3] Y.W. Chin, M.J. Balunas, H.B. Chai, A.D. Kinghorn, Drug discovery from natural sources, *AAPS Journal* 8 (2006) E239–E253.
- [4] K.N. Venugopala, V.B. Odhav, Review on natural coumarin lead compounds for their pharmacological activity, *BioMed Research International* (2013) 963248, <http://dx.doi.org/10.1155/2013/963248>.
- [5] M.J. Matos, F. Pérez-Cruz, S. Vazquez-Rodriguez, E. Uriarte, L. Santana, F. Borges, C. Olea-Azar, Remarkable antioxidant properties of a series of hydroxy-3-aryl coumarins, *Bioorganic & Medicinal Chemistry* 21 (2013) 3900–3906.
- [6] R.A. Davis, D. Vullo, A. Maresca, C.T. Supuran, S.A. Poulsen, Natural product coumarins that inhibit human carbonic anhydrases, *Bioorganic & Medicinal Chemistry* 21 (2013) 1539–1543.
- [7] A.S. Awaad, N.A. Al-Jaber, G.A. Soliman, M.R. Al-Outhman, M.E. Zain, J.E. Moses, R.M. El-Meligy, New biological activities of *Casimiroa edulis* leaf extract and isolated compounds, *Phytotherapy Research* 26 (2012) 452–457.
- [8] O.S. Kwon, J.S. Choi, M.N. Islam, Y.S. Kim, H.P. Kim, Inhibition of 5-lipoxygenase and skin inflammation by the aerial parts of *Artemisia*

- capillaritis and its constituents, *Archives of Pharmacal Research* 34 (2011) 1561–1569.
- [9] P.J. Dasiewicz, J.M. Conlon, W.G. Anderson, Cardiovascular and vasoconstrictive actions of skate bradykinin in the little skate, *Leucoraja erinacea* (Elasmobranchii), *General and Comparative Endocrinology* 174 (2011) 89–96.
- [10] M. Atmaca, H.M. Bilgin, B.D. Obay, H. Diken, M. Kelle, E. Kale, The hepatoprotective effect of coumarin and coumarin derivatives on carbon tetrachloride-induced hepatic injury by antioxidative activities in rats, *Journal of Physiology and Biochemistry* 67 (2011) 569–576.
- [11] A. Karmase, R. Birari, K.K. Bhutani, Evaluation of anti-obesity effect of Aegle marmelos leaves, *Phytomedicine* 20 (2013) 805–812.
- [12] S.R. Subramaniam, E.M. Ellis, Neuroprotective effects of umbelliferone and esculetin in a mouse model of Parkinson's disease, *Journal of Neuroscience Research* 91 (2013) 453–461.
- [13] B. Ramesh, K.V. Pugalendi, Antihyperlipidemic and antidiabetic effects of umbelliferone in streptozotocin diabetic rats, *Yale Journal of Biology and Medicine* 78 (2005) 189–196.
- [14] J.F. Vasconcelos, M.M. Teixeira, J.M. Barbosa-Filho, M.F. Agra, X.P. Nunes, A.M. Giulietti, R. Ribeiro-Dos-Santos, M.B. Soares, Effects of umbelliferone in a murine model of allergic airway inflammation, *European Journal of Pharmacology* 609 (2009) 126–131.
- [15] K.C. Fylaktakidou, D.J. Hadjipavlou-Litina, K.E. Litinas, D.N. Nicolaidis, Natural and synthetic coumarin derivatives with anti-inflammatory/antioxidant activities, *Current Pharmaceutical Design* 10 (2004) 3813–3833.
- [16] D. Ramanitrahimbola, D.A. Rakotondramanana, P. Rasoanaivo, A. Randrianisoa, S. Ratsimamanga, G. Palazzino, C. Galeffi, M. Nicoletti, Bronchodilator activity of *Phymatodes scolopendria* (Burm.) Ching and its bioactive constituent, *Journal of Ethnopharmacology* 102 (2005) 400–407.
- [17] M. Iranshahy, M. Iranshahi, Traditional uses, phytochemistry and pharmacology of asafoetida (*Ferula assa-foetida* oleo-gum-resin)-a review, *Journal of Ethnopharmacology* 134 (2011) 1–10.
- [18] J.C. Jung, S. Oh, Practical synthesis of hydroxychromenes and evaluation of their biological activity, *Molecules* 17 (2012) 240–247.
- [19] S. Siddiqui, N.S. Redhu, O.O. Ojo, B. Liu, N. Irechukwu, C. Billington, L. Janssen, M.L. Moir, Emerging airway smooth muscle targets to treat asthma, *Pulmonary Pharmacology & Therapeutics* 26 (2013) 132–144.
- [20] J.R. Houlst, M. Payá, Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential, *General Pharmacology* 27 (1996) 713–722.
- [21] C.K. Billington, O.O. Ojo, R.B. Penn, S. Ito, cAMP regulation of airway smooth muscle function, *Pulmonary Pharmacology & Therapeutics* 26 (2013) 112–120.
- [22] R. Zhuge, R. Bao, K.E. Fogarty, L.M. Lifshitz, Ca^{2+} sparks act as potent regulators of excitation-contraction coupling in airway smooth muscle, *Journal of Biological Chemistry* 285 (2010) 2203–2210.
- [23] J.H. Jagger, V.A. Porter, W.J. Lederer, M.T. Nelson, Calcium sparks in smooth muscle, *American Journal of Physiology – Cell Physiology* 278 (2000) C235–C256.
- [24] L.B. Bergantin, C.F. Souza, R.M. Ferreira, S.S. Smaili, N.H. Jurkiewicz, A. Caricati-Neto, A. Jurkiewicz, Novel model for “calcium paradox” in sympathetic transmission of smooth muscles: role of cyclic AMP pathway, *Cell Calcium* 54 (2013) 202–212.
- [25] H. Meurs, T.A. Oenema, L.E. Kistemaker, R. Gosens, A new perspective on muscarinic receptor antagonism in obstructive airways diseases, *Current Opinion in Pharmacology* 13 (2013) 316–323.
- [26] A.F. Roffel, C.R. Elzinga, J. Zaagsma, Muscarinic M3 receptors mediate contraction of human central and peripheral airway smooth muscle, *Pulmonary Pharmacology* 3 (1990) 47–51.
- [27] H.C. Huang, C.R. Lee, Y.I. Weng, M.C. Lee, Y.T. Lee, Vasodilator effect of scoparone (6,7-dimethoxycoumarin) from a Chinese herb, *European Journal of Pharmacology* 218 (1992) 123–128.
- [28] Y.H. Choi, G.H. Yan, Anti-allergic effects of scoparone on mast cell-mediated allergy model, *Phytomedicine* 16 (2009) 1089–1094.
- [29] H. Hakonarson, M.M. Grunstein, Regulation of second messengers associated with airway smooth muscle contraction and relaxation, *American Journal of Respiratory and Critical Care Medicine* 158 (1998) S115–S122.
- [30] I.V. Tetko, J. Gasteiger, R. Todeschini, A. Mauri, D. Livingstone, P. Ertl, V.A. Palyulin, E.V. Radchenko, N.S. Zefirov, A.S. Makarenko, V.Y. Tanchuk, V.V. Prokopenko, Virtual computational chemistry laboratory—design and description, *Journal of Computer-Aided Molecular Design* 19 (2005) 453–463.
- [31] <http://www.vcclab.org>.
- [32] H. Van de Waterbeemd, D.A. Smith, B.C. Jones, Lipophilicity in PK design: methyl, ethyl, futile, *Journal of Computer-Aided Molecular Design* 15 (2001) 273–286.
- [33] G. Lunn, B.J. Banks, R. Crook, N. Feeder, A. Pettman, Y. Sabnis, Discovery and synthesis of a new class of opioid ligand having a 3-azabicyclo[3.1.0]hexane core. An example of a ‘magic methyl’ giving a 35-fold improvement in binding, *Bioorganic & Medicinal Chemistry Letters* 21 (2011) 4608–4611.
- [34] I.V. Tetko, Computing chemistry on the web, *Drug Discovery Today* 10 (2005) 1497–1500.
- [35] W.L.F. Armarego, D.D. Perrin, *Purification of Laboratory Chemicals*, fourth ed., Pergamon, Oxford, 1988 (Chapter 1).
- [36] J.S. Fedan, M.R. Van Scott, R.A. Johnston, Pharmacological techniques for the in vitro study of airways, *Journal of Pharmacological and Toxicological Methods* 45 (2001) 159–174.
- [37] C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, *Advanced Drug Delivery Reviews* 46 (2001) 3–26.
- [38] <http://www.molinspiration.com/cgi-bin/properties/>.